CANVAS – canagliflozin and cardiovascular or renal influence for diabetes mellitus type 2

Czech version

Authors: Vítovec J. ¹; Špinar J. ²; Špinarová L. ¹
Authors‘ workplace: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně ¹; Lékařská fakulta MU Brno ²
Published in: Kardiol Rev Int Med 2019, 21(1): 15-18

Overview

Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycaemia as well as blood pressure, body weight, and albuminuria in people with diabetes. The CANVAS Programme integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Conclusions: In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a significantly lower risk of cardiovascular events than those who received placebo. A boundary higher risk of amputation, primarily at the level of the toe or metatarsus was observed in the study. These complications, however, were not proved in subsequent observational databases.

Keywords:

cardiovascular and renal safety – type 2 diabetes mellitus – canagliflozin – programme CANVAS

Sources

1. Niessner A, Tamargo J, Koller L et al. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the ESC Working Group on Cardiovascular Pharmacotherapy. Eur Heart J 2018; 39(24): 2274– 2281. doi: 10.1093/ eurheartj/ ehx625.

2. Neal B, Perkovic V, Mahaffey KW et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644– 657. doi: 10.1056/ NEJMoa1611925.

3. Rådholm K, Figtree G, Perkovic V et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Results From the CANVAS Program. Circulation 2018; 138(5): 458– 468. doi: 10.1161/ CIRCULATIONAHA.118.034222.

4. Edelsberger T. Glukuretika (inhibitory SGLT2, glifloziny) v léčbě diabetu. Remedia 2011; 21: 46– 53.

5. Heerspink HJ, Perkins BA, Fitchett DH et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134(10): 752– 772. doi: 10.1161/ CIRCULATIONAHA.116.021887.

6. Wilding JP, Woo V, Soler NG et al. Sustained effectiveness of dapagliflozin over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. Diabetes 2010; 59 (Suppl. 1): Abstract 0021– LB.

7. Adamíková A. Kanagliflozin – místo v léčbě diabetes mellitus 2. typu. Farmakoterapeutická Revue 2018; 1: 8– 13.

8. SPC Invokana. Dostupné na: http:/ / www.sukl.cz/ modules/ medication/ detail.php?code=0194605&tab=prices.

9. Yuan Z, DeFalco FJ, Ryan PB et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. Diabetes Obes Metab 2018; 20(3): 582– 589. doi: 10.1111/ dom.13115.

10. Ryan PB, Buse JB, Schuemie MJ et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 2018; 20(11): 2585– 2597. doi: 10.1111/ dom.13424.

11. Bode B, Stenlöf K, Harris S. Long-term efficacy and safety of CANA over 104 weeks in patients aged 55 to 80 years with type 2 diabetes. Diabetes Obes Metab 2015; 17(3): 294– 303. doi: 10.1111/ dom.12428.

12. Jardine MJ, Mahaffey KW, Neal B et al. The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design and baseline characteristics. Am J Nephrol 2017; 46(6): 462– 472. doi: 10.1159/ 000484633.

13. Palmer C. CREDENCE canagliflozin trial halted because of efficacy. Cardiology News 2018. Available at: https://www.mdedge.com/cardiology/article/170423/diabetes/credence-canagliflozin-trial-halted-because-efficacy.

Labels

Paediatric cardiology Internal medicine Cardiac surgery Cardiology

The most common causes of hospitalisation and death in patients with diabetes – results of the National Diabetology Registry

Study DECLARE confirmed positive effect of dapagliflozin

Diabetes mellitus and cancer – UPDATE

Screening of asymptomatic carotid atherosclerosis in diabetic patients and its association with ankle-brachial index

Comparison of the benefits of FGM and CGM for different clinical scenarios in patients with type 1 diabetes mellitus

Could we soon have the final evidence of cardiovascular safety of DPP-4 inhibitors?

Complex management of diabetic patients with membrovascular arterial disease and multiorganomultivascular disease

Adherence to therapy in arterial hypertension

The role of nebivolol in the treatment of cardiovascular diseases

Article was published in

Cardiology Review

2019 Issue 1